101 related articles for article (PubMed ID: 38334171)
1. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract][Full Text] [Related]
2. CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K/AKT/mTOR activation.
Li Y; Wang Z; Yang J; Sun Y; He Y; Wang Y; Chen X; Liang Y; Zhang N; Wang X; Zhao W; Hu G; Yang Q
Mol Cancer; 2024 May; 23(1):102. PubMed ID: 38755678
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mTOR pathway.
Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
[TBL] [Abstract][Full Text] [Related]
4. Metadherin inhibits chemosensitivity of triple-negative breast cancer to paclitaxel via activation of AKT/GSK-3β signaling pathway.
Chang Y; Jia HQ; Xu B; Yang L; Xu YT; Zhang JY; Wang MQ; Yang LX; Song ZC
Chem Biol Drug Des; 2024 Jan; 103(1):e14416. PubMed ID: 38093418
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of REG3A promotes tumorigenic behavior in triple negative breast cancer cells.
Jin X; Yang S; Lu X; Chen X; Dai W
Breast Cancer Res; 2024 Jun; 26(1):92. PubMed ID: 38840145
[TBL] [Abstract][Full Text] [Related]
6. Curcumin suppresses metastasis of triple-negative breast cancer cells by modulating EMT signaling pathways: An integrated study of bioinformatics analysis.
Chen Z; Lu P; Li M; Zhang Q; He T; Gan L
Medicine (Baltimore); 2024 Feb; 103(8):e37264. PubMed ID: 38394486
[TBL] [Abstract][Full Text] [Related]
7. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
Abd El-Aziz YS; Toit-Thompson TD; McKay MJ; Molloy MP; Stoner S; McDowell B; Moon E; Sioson L; Sheen A; Chou A; Gill AJ; Jansson PJ; Sahni S
Eur J Pharmacol; 2024 Jun; 973():176568. PubMed ID: 38604544
[TBL] [Abstract][Full Text] [Related]
8. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract][Full Text] [Related]
9. The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling.
Huang M; Yu X; Wang Q; Jiang Z; Li X; Chen W; Song C
Cell Commun Signal; 2024 Jan; 22(1):35. PubMed ID: 38216949
[TBL] [Abstract][Full Text] [Related]
10. YY1 mediated DCUN1D5 transcriptional activation promotes triple-negative breast cancer progression by targeting FN1/PI3K/AKT pathway.
Lin Y; Li Y; Chen X; Jin X; Jiang M; Xiao H; Chen L; Chen M; Zhang W; Chen H; Nie Q; Guo R; Guo W; Fu F; Wang C
Biol Direct; 2024 Jun; 19(1):42. PubMed ID: 38831379
[TBL] [Abstract][Full Text] [Related]
11. Rujifang inhibits triple-negative breast cancer growth via the PI3K/AKT pathway.
Jia W; Lin X; Chen X; Li H; Zhang X; Zhang Y; Chen Y; Wang B; Chen X; Chen J; Tian H
J Ethnopharmacol; 2024 Jun; 327():118011. PubMed ID: 38467320
[TBL] [Abstract][Full Text] [Related]
12. HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.
Zong B; Sun L; Peng Y; Wang Y; Yu Y; Lei J; Zhang Y; Guo S; Li K; Liu S
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036395
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.
Zhao PW; Cui JX; Wang XM
Pharmacogenomics J; 2024 Feb; 24(2):5. PubMed ID: 38378770
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
Ganesan P; Moulder S; Lee JJ; Janku F; Valero V; Zinner RG; Naing A; Fu S; Tsimberidou AM; Hong D; Stephen B; Stephens P; Yelensky R; Meric-Bernstam F; Kurzrock R; Wheler JJ
Mol Cancer Ther; 2014 Dec; 13(12):3175-84. PubMed ID: 25253784
[TBL] [Abstract][Full Text] [Related]
16. Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
Bullock KK; Shattuck-Brandt R; Scalise C; Luo W; Chen SC; Saleh N; Gonzalez-Ericsson PI; Garcia G; Sanders ME; Ayers GD; Yan C; Richmond A
Cancer Lett; 2024 Apr; 586():216681. PubMed ID: 38311054
[TBL] [Abstract][Full Text] [Related]
17. Ursolic acid inhibits the proliferation of triple‑negative breast cancer stem‑like cells through NRF2‑mediated ferroptosis.
Yang X; Liang B; Zhang L; Zhang M; Ma M; Qing L; Yang H; Huang G; Zhao J
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38847277
[TBL] [Abstract][Full Text] [Related]
18. TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.
Iachettini S; Terrenato I; Porru M; Di Vito S; Rizzo A; D'Angelo C; Petti E; Dinami R; Maresca C; Di Benedetto A; Palange A; Mulè A; Santoro A; Palazzo A; Fuso P; Stoppacciaro A; Vici P; Filomeno L; Di Lisa FS; Arcuri T; Krasniqi E; Fabi A; Biroccio A; Zizza P
J Exp Clin Cancer Res; 2024 Mar; 43(1):75. PubMed ID: 38459559
[TBL] [Abstract][Full Text] [Related]
19. Linc00707 regulates autophagy and promotes the progression of triple negative breast cancer by activation of PI3K/AKT/mTOR pathway.
Li H; Liu Q; Hu Y; Yin C; Zhang Y; Gao P
Cell Death Discov; 2024 Mar; 10(1):138. PubMed ID: 38485945
[TBL] [Abstract][Full Text] [Related]
20. ANGPTL3 diminishes the resistance of ovarian cancer to paclitaxel by blocking the PI3K-AKT-mTOR signaling pathway.
Wu D; Liu J; Yang X; Wu Z; Wang T; Xiao M
Heliyon; 2024 Jun; 10(11):e31520. PubMed ID: 38828336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
